Drug Trial Radar · NCT03985878
A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)
Last checked: Nov 20, 2026Latest source record: Aug 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
15
Actual
Start
Jun 26, 2019
Primary completion
Aug 31, 2022
Study completion Aug 31, 2022
Sponsor
- Lead sponsor
- Sarepta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 2 years, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this extension study is to evaluate the ongoing safety and tolerability of additional treatment with eteplirsen administered once weekly by intravenous (IV) infusion in male participants with DMD who have successfully completed the 96-week eteplirsen Study 4658-102.
Conditions
- Duchenne Muscular Dystrophy
Interventions
EteplirsenDrug
Eteplirsen IV infusion once weekly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to 162 weeks
- Number of Participants Experiencing Death Due to Adverse EventsTime frame: Up to 162 weeks
- Number of Participants Experiencing Adverse Events of Special Interest (AESIs)Time frame: Up to 162 weeks
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
UZ-Gent
Ghent, Belgium
Hopital Trousseau, Bâtiment lemariey
Paris, France
Fondazione Policlinico Universitario Agostino Gemelli, UOC Neuropsichiatria Infantile
Rome, Italy
UCL Great Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre
London, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.